Behavioural Health Development FDA Approval Production 
pharmaphorum
OCTOBER 2, 2020
Like its earlier digital therapies for alcohol misuse and depression , Modia’s earlier-than-expected rollout stems from legislation that has made it possible to secure reimbursement for certain digital products for psychiatric disorders during the COVID-19 pandemic.
pharmaphorum
MARCH 21, 2022
In 2021, the behavioural health company and Sumitomo Dainippon Pharma Co. in Japan announced their partnership to develop and commercialise prescription digital therapeutics and general wellness products to treat social anxiety disorder, generalised anxiety, and major depressive disorder.
Expert insights. Personalized for you.
98 
Let's personalize your content